Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026

Climb Bio, Inc.

Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.
FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.
Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.
Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.
CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.